SomaScan® Proteomics Assay

Illumina Enters Co-Development Partnership with SomaLogic to Help Researchers’ Understanding of Biology and Disease

Partnership will Accelerate Next-Generation Sequencing into Fastest-Growing Area of Proteomics Market with Ultra-high Throughput, Ultra-high Plexity Workflow
Press Release

SAN DIEGO, January 6, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan® Proteomics Assay onto Illumina's current and future high throughput next-generation sequencing (NGS) platforms. This partnership accelerates the rapidly growing high throughput sector of the proteomics market.

Subscribe to SomaScan® Proteomics Assay